50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Myelodysplastic Syndromes Poster III

Monday, December 8, 2008: 5:30 PM-7:30 PM

Hall A (Moscone Center)

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

John F Seymour, MBBS, PhD, FRACP¹^*, Pierre Fenaux, MD, PhD²^*, Lewis B. Silverman, MD³, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath⁴, Eva Hellström-Lindberg, MD, PhD⁵^*, Valeria Santini, MD⁶^*, Alan F. List, MD⁷, Steven D. Gore, MD⁸, Jay Backstrom, MD, MPH⁹^*, David McKenzie, MS⁹^* and C. L. Beach, PharmD⁹^*

¹Dept of Haematology, Peter MacCallum Cancer Institute, Victoria, Australia
²Hospital Avicenne, Bobigny, France
³Pediatric Oncology, Dana-Farber Cancer Inst., Boston, MA
⁴Department of Haematological Medicine, Kings College London, London, United Kingdom
⁵Karolinska University Hospital, Stockholm, Sweden
⁶Hematology, Azienda Ospedaliera Careggi, Firenze, Italy
⁷H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁸The Sidney Kimmel Comprehensive Cancer Ctr. at Johns Hopkins, Baltimore, MD
⁹Celgene, Overland Park, KS

3630

Cytogenetic Analysis and FISH in the Evaluation of Patients with MDS: A Retrospective Analysis of Concordance Rate, Utility and Benefit of Performing Both Studies Simultaneously

Jamile Shammo¹^*, Alla Gimelfarb¹^*, Wei-Tong Hsu²^*, Irene Dehghan- Paz¹^*, Parameswaran Venugopal¹^*, Melissa L. Larson, MD¹, Henry C. Fung³^*, Mohamed Farhat¹^*, Amy Rizman¹^*, Jerome Loew²^* and Stephanie A. Gregory¹^*

¹Hematology, Rush University Hospital, Chicago, IL
²Pathology, Rush University Hospital, Chicago, IL
³Section of Hematology & Stem Cell Transplantation, Rush University Medical Center, Chicago, IL

3631

Increased Reactive Oxygen Species Induced by NUP98-HOXD13 Fusion Gene in MDS Mouse Model

Yang Jo Chung, PhD and Peter D. Aplan, MD

Genetics Branch, NIH, NCI, CCR, Bethesda, MD

3632

Efficacy of Hypo-Methylating Agents in the Treatment of Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ambuj Kumar, MD, MPH¹^*, Alan F. List, MD², Rahul Mhaskar²^* and Benjamin Djulbegovic, MD, PhD³

¹Moffitt Cancer Center, Tampa, FL
²H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
³H. Lee Moffitt Cancer Center, Tampa, FL

3633

Low Absolute Lymphocyte Count (ALC) at Diagnosis Is An IPSS-Independent Predictor of Poorer Survival in Myelodysplastic Syndromes (MDS)

Nisha L Jacobs¹^*, Shernan G Holtan, MD², Luis F Porrata, MD², Svetomir N Markovic, MD, PhD²^*, Ayalew Tefferi, MD² and David P. Steensma, MD, FACP²

¹Medicine, Mayo Clinic Graduate School of Medicine, Rochester, MN
²Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN

3634

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes: A Prospective Validation Study in Low-Risk Patients with Normal Karyotype

Kiyoyuki Ogata¹, Matteo G. Della Porta²^*, Luca Malcovati²^*, Cristina Picone²^*, Norio Yokose³^*, Akira Matsuda⁴^*, Taishi Yamashita¹^*, Hideto Tamura¹^*, Junichi Tsukada⁵^*, Kazuo Dan¹ and Mario Cazzola²

¹Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan
²Department of Hematology Oncology, University of Pavia & Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
³Department of Internal Medicine, Chiba Hokusoh Hospital, Nippon Medical School, Chiba
⁴Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
⁵First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

3635

MDS Marrow Stroma Is Characterized by Distinct Epigenetic Alterations

Tushar D Bhagat¹^*, Emily Spaulding²^*, Davendra Sohal¹^*, Yongkai Mo¹, Mario Marcondes²^*, Li Zhou¹^*, Reid Thompson¹^*, John Greally¹^*, H. Joachim Deeg² and Amit Verma¹

¹Albert Einstein College of Medicine, Bronx, NY
²Fred Hutchinson Cancer Research Center, Seattle, WA

3636

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

Pierre Fenaux, MD, PhD¹^*, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath², Eva Hellström-Lindberg, MD, PhD³^*, Valeria Santini, MD⁴^*, Norbert Gattermann, MD⁵, Guillermo Sanz, MD, PhD⁶, Alan F. List, MD⁷, Steven D. Gore, MD⁸, John F Seymour, MBBS, PhD, FRACP⁹^*, Jay Backstrom, MD, MPH¹⁰^*, Linda Zimmerman, BSN¹⁰^*, David McKenzie, MS¹⁰^*, C. L. Beach, PharmD¹⁰^* and Lewis B. Silverman, MD¹¹

¹Hôpital Avicenne/ Université Paris 13, Bobigny, France
²Department of Haematological Medicine, Kings College London, London, United Kingdom
³Karolinska University Hospital, Stockholm, Sweden
⁴Hematology, Azienda Ospedaliera Careggi, Firenze, Italy
⁵Heinrich-Heine-University, Düsseldorf, Germany
⁶Dept. of Hematology, Hospital Universitario La Fe, Valencia, Spain
⁷H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁸The Sidney Kimmel Comprehensive Cancer Ctr. at Johns Hopkins, Baltimore, MD
⁹Dept of Haematology, Peter MacCallum Cancer Institute, Victoria, Australia
¹⁰Celgene, Overland Park, KS
¹¹Pediatric Oncology, Dana-Farber Cancer Inst., Boston, MA

3637

Expression of WT-1 mRNA in Peripheral Blood from Myelodysplastic Syndromes

Hideto Tamura, MD, PhD¹, Kazuo Dan¹, Norio Yokose²^*, Rika Iwakiri³^*, Masatsugu Ohta³^*, Hisashi Sakamaki, MD, PhD⁴^*, Kaoru Tohyama⁵^*, Asaka Kondo¹^*, Kyoko Nakamura¹^*, Taishi Yamashita¹^*, Takashi Tsuji⁶^* and Kiyoyuki Ogata, MD, PhD¹

¹Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan
²Department of Internal Medicine, Chiba Hokusoh Hospital, Nippon Medical School, Chiba
³Department of Hematology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
⁴Department of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
⁵Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan
⁶Department of Biological Science and Technology, Tokyo University of Science, Chiba, Japan

3638

Susceptibility towards Irradiation-Induced Bone Marrow (BM) Dysplasia in Vivo Is Determined by the BM Vasculogenic Phenotype: Correlation with MDS Patients BM Samples

Catarina Osorio¹^*, Catia Igreja¹^*, Rita Fragoso¹^*, Manuela Ferreira¹^*, Tania Carvalho¹^*, Andreia Mendonca²^*, Maria Gomes Silva²^* and Sergio Dias¹

¹Angiogenesis Lab, CIPM, Portuguese Institute of Oncology, Lisbon, Portugal
²Hematology, Portuguese Institute of Oncology, Lisbon, Portugal

3639

Treatment of Poor Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia with a Combination of 5-Azacytidine and Valproic Acid

Andrea Kuendgen¹^*, Gesine Bug²^*, Oliver G. Ottmann²^*, Detlef Haase³^*, Barbara Hildebrandt⁴^*, Kerstin Habersang¹^*, Ariane Dienst¹^*, Rainer Haas¹^*, Ulrich Germing¹^* and Norbert Gattermann¹

¹Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany
²Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Frankfurt a.M., Germany
³Hematology and Oncology, University of Goettingen, Goettingen, Germany
⁴Human Genetics, University of Düsseldorf, Düsseldorf, Germany

3640

Gain of 1q as a Potential Adverse Prognostic Marker in Myelodysplastic Syndrome : Comparison with International Prognostic Scoring System Variables

Hyun-Kyung Park¹^*, Dong Soon Lee¹^*, Hye Ryun Lee¹^*, Han Ik Cho¹^*, Hyun Kyung Kim¹^*, Sung-Soo Yoon² and Byoung Kook Kim²

¹Dept. of laboratory medicine, Seoul National University College of Medicine, Seoul, South Korea
²Department of internal medicine, Seoul National University, Seoul, South Korea

3641

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)

Andrea Pellagatti¹^*, Eva Hellström-Lindberg², Aristoteles Giagounidis³, Janet Perry¹^*, Luca Malcovati⁴^*, Matteo Della Porta⁴^*, Martin Jädersten²^*, Sally Killick⁵^*, Davendra P. Sohal⁶^*, Amit Verma⁶, Mario Cazzola⁴, James S. Wainscoat¹^* and Jacqueline Boultwood¹

¹LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, United Kingdom
²Karolinska Institutet, Department of Medicine, Division of Hematology, Stockholm, Sweden
³Medizinische Klinik II, St Johannes Hospital, Duisburg, Germany
⁴Division of Hematology, University of Pavia Medical School, IRCCS Policlinico S. Matteo, Pavia, Italy
⁵Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
⁶Albert Einstein College of Medicine, Bronx, NY

3642

Gene Expression Profiling of CD34⁺ Cells in Patients with Myelodysplastic Syndromes

Andrea Pellagatti¹^*, Mario Cazzola², Aristoteles Giagounidis³, Janet Perry¹^*, Luca Malcovati²^*, Matteo Della Porta²^*, Martin Jädersten⁴^*, Sally Killick⁵^*, Eva Hellström-Lindberg⁴, James S. Wainscoat¹^* and Jacqueline Boultwood¹

¹LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, United Kingdom
²Division of Hematology, University of Pavia Medical School, IRCCS Policlinico S. Matteo, Pavia, Italy
³Medizinische Klinik II, St Johannes Hospital, Duisburg, Germany, Duisburg, Germany
⁴Karolinska Institutet, Department of Medicine, Division of Hematology, Stockholm, Sweden
⁵Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom

3643

RUNX1 Mutations Play a Major Role in the Progression of MDS to S-AML Following MDS: A Genetic and Cytogenetic Analysis of Sequential Samples

Frank Dicker, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD and Susanne Schnittger, PhD

MLL Munich Leukemia Laboratory GmbH, Munich, Germany

3644

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

Amelia A Langston, MD, Sujatha Murali, MD^*, Stephanie McMillan, RN^*, Leonard T. Heffner, MD^*, Sagar Lonial, MD, Edmund K. Waller, MD, PhD, Christopher R. Flowers, MD, Jonathan Kaufman, MD^*, Morgan L. McLemore, MD, Rajni Sinha, MD^*, Mary J Lechowicz, MD^*, H. Jean Khoury, MD and Elliott F. Winton, MD

Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

3645

MicroRNA Expression Profiling of High and Low Risk MDS

Joop Gaken, PhD¹^*, Azim M Mohamedali, PhD¹^*, Natalie Twine¹^*, Nigel Westwood, PhD, Csci, FIBMS¹^*, Barbara Czepulkowski²^*, Saousan Chehade¹^*, Lynn S Quek³^*, Nicholas Lea, PhD¹^* and Ghulam J Mufti, MBBS, DM, FRCP, FRCPath⁴

¹Haematological Medicine, Kings College London, London, United Kingdom
²Haematological Medicine, King's College London, London, United Kingdom
³Haematology, King's College Hospital NHS Trust, London, UK, London, United Kingdom
⁴Department of Haematological Medicine, Kings College London, London, United Kingdom

3646

Single Nucleotide Polymorphisms in the Human TNFα Gene Are Associated with Neutropenia and Anemia in a Cohort of Patients with Myelodysplastic Syndrome

Aric Parnes, MD¹, Sarah Nikiforow, M.D., Ph.D.¹^*, Nancy Berliner, MD² and K. Gary J. Vanasse, MD³

¹Medicine, Yale School of Medicine, New Haven, CT
²Brigham & Women's Hospital, Boston, MA
³Medicine, Brigham and Women's Hospital, Boston, MA

3647

Altered Naive and Memory T Cell Homeostasis and Immunosenescence Characterize Younger Patients with Immunosuppressive-Responsive Myelodysplastic Syndrome

JianXiang Zou, MD¹^*, Dana E Rollison, PhD², David Boulware, MS³^*, Elaine M. Sloand, MD⁴^*, Loretta Pfannes, BS⁵^*, Fanqi Bai, MD¹^*, Jeffrey S. Painter, BS¹^*, Sheng Wei, MD¹^*, Denise Cosgrove, RN⁶^*, Alan F. List, MD⁷ and P.K. Epling-Burnette, PhD⁸

¹Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL
²Risk Assessment, Detectio and Intervention Program, Moffitt Cancer Center, Tampa, FL
³Biostatistics Program, H. Lee Moffitt Cancer Center, Tampa, FL
⁴National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
⁵Hematology Branch, National Institutes of Health, Bethesda, MD
⁶Malignant Hematology Division, H. Lee Moffitt Cancer Center, Tampa, FL
⁷H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁸Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

3648

5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/ High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial

Maria Teresa Voso¹^*, Valeria Santini²^*, Carlo Finelli³^*, Lorenza Borin⁴^*, Emanuele Angelucci⁵, Giuseppe Fioritoni⁶^*, Benedetta Neri⁷^*, Agostino Cortellezi⁸^*, Oreste Villani⁹^*, Francesco Buccisano¹⁰, Giovanni Martinelli¹¹^*, Maria Concetta Petti¹²^*, Gina Zini¹^*, Alfonso Piciocchi¹³^*, Paola Fazi¹³^*, Giuliana Alimena¹⁴, Marco Gobbi¹⁵^*, Vincenzo Liso¹⁶^* and Giuseppe Leone¹⁷^*

¹Hematology, Universita' Cattolica S. Cuore, Rome, Italy
²Hematology, Azienda Ospedaliera Careggi, Firenze, Italy
³Hematology, University of Bologna
⁴Internal Medicine, Universita' di Milano-Bicocca, Monza
⁵Ematologia-Cagliari, Italy
⁶Hematology, Civic Hospital, Pescara
⁷Hematology, Ospedale S. Eugenio, Rome
⁸Hematology, IRCCS Regina Elena, Milano
⁹Hematology, Centro di Riferimento Oncologico Basilicata, Rionero in Vulture
¹⁰Hematology, University Tor Vergata, Roma
¹¹Hematology, University of Bologna, Bologna
¹²Hematology, Istituto Oncologico Regina Elena, Roma
¹³Gimema Data Center, Rome, Italy
¹⁴Division of Hematology, University of Rome La Sapienza
¹⁵Hematology, University of Genova
¹⁶Hematology, Università degli Studi di Bari
¹⁷Hematology, Universita' Cattolica S. Cuore, Rome

3649

A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R₂ MRI

Yoo-Hong Min¹, Hyeoung Joon Kim², Kyoo Hyung Lee³, Sung-Soo Yoon⁴, Jae Hoon Lee⁵, Hee-Sook Park⁶^*, Jin Seok Kim⁷^*, Ho Young Kim⁸^*, Hyeok Shim⁹^*, Chu-Myong Seong¹⁰, Chul Soo Kim¹¹, Jooseop Chung¹², Myung Soo Hyun¹³^*, Deog-Yeon Jo¹⁴, Chul Won Jung¹⁵, Sang Kyun Sohn¹⁶, Hwi-Joong Yoon¹⁷, Byung Soo Kim¹⁸, Young-Don Joo¹⁹, Chi-Young Park²⁰^* and June-Won Cheong⁷^*

¹Yonsei University College of Medicine, The Korean Society of Hematology AML/MDS Working Party, Seoul, South Korea
²Chonnam National University Hwasun Hospital, Kwangju, South Korea
³Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
⁴Seoul National University Hospital, Seoul, South Korea
⁵Gachon University Gil Hospital, Incheon
⁶Soon Chun Hyang University Hospital, Seoul, South Korea
⁷Yonsei University College of Medicine, Seoul, South Korea
⁸Hallym University Sacred Heart Hospital, Hallym University Medical Center, Anyang, South Korea
⁹Wonkwang University School of Medicine, Iksan, South Korea
¹⁰Ewha Womans University College of Medicine,, Seoul, South Korea
¹¹Inha University Hospital, Seoul, South Korea
¹²Pusan National Unveristy Hospital, Busan, South Korea
¹³Yeungnam University College of Medicine, Daegu, South Korea
¹⁴Chungnam National University, Daejeon, South Korea
¹⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
¹⁶Kyungpook National University Hospital, Daegu, South Korea
¹⁷Kyung Hee University School of Medicine, Seoul, South Korea
¹⁸Korea University Medical Center, Seoul, South Korea
¹⁹Inje University Paik Hospital, Busan, South Korea
²⁰College of Medicine, Chosun University, Gwangju, South Korea

3650

Analysis of the αβ T Cell Receptor Repertoire in Advanced Myelodysplastic Syndrome

Paulo V Campregher, MD¹^*, Santosh K Srivastava, PhD²^*, Nobuharu Fujii, MD, PhD¹^*, H. Joachim Deeg, MD¹, Harlan S Robins, PhD²^* and Edus Warren, MD, PhD¹

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
²Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA

3651

Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Mark Kirschbaum¹, Ivana Gojo², Stuart L Goldberg³, Lisa Kujawski⁴^*, Ehab Atallah⁵^*, Peter Marks⁶, Jose Garcia-Vargas⁷^*, Syed Rizvi⁷, Donna Di Gravio⁷^*, Janet Ahern⁷^* and Jean-Pierre Issa⁸

¹City of Hope National Medical Center, Duarte, CA
²University of Maryland Medical Center, Baltimore, MD
³John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
⁴University of Michigan, Ann Arbor, MI
⁵Medical College of Wisconsin, Milwaukee, WI
⁶Yale University School of Medicine, New Haven, CT
⁷Merck & Co Inc., Upper Gwynedd, PA
⁸M.D. Anderson Cancer Center, University of Texas, Houston, TX

3652

Flow Cytometric Findings Indicative of Myelodysplasia Differ Depending on the Karyotype

Wolfgang Kern, MD, Torsten Haferlach, MD, Susanne Schnittger, PhD and Claudia Haferlach, MD

MLL Munich Leukemia Laboratory GmbH, Munich, Germany

3653

SNP Arrays in Patients with Myelodysplastic Syndromes and Ringed Sideroblasts: A Karyotypic and Disease Association Analysis

Rami Khoriaty, M.D.¹^*, Lukasz P. Gondek, MD²^*, Bartlomiej P Przychodzen²^*, Theodore Ghazal²^*, Abdo Haddad, M.D.²^* and Jaroslaw Maciejewski, M.D., PhD²

¹Internal Medicine Residency Program, Cleveland Clinic, Cleveland, OH
²Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

3654

Dysregulated Distribution of Naïve and Memory FoxP3 Positive Regulatory T-Cells Associated with Anemia in Myelodysplastic Syndrome (MDS)

Chiharu Sugimori, MD¹^*, JianXiang Zou, MD²^*, Christine O'Keefe, PhD³^*, Michael Clemente, MS⁴^*, Tie-Ying Wei, BS⁵^*, Jaroslaw Maciejewski⁶, Thomas P. Loughran Jr., MD⁷, Ron Paquette, MD⁸, Alan F. List, MD⁹ and P.K. Epling-Burnette, PhD⁵

¹Immunology Program, H. Lee Moffitt Cancer Center, Tampa, HI
²Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL
³Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH
⁴Cleveland Clinic, Taussig Cancer Institute R40, Cleveland, OH
⁵Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
⁷Penn State Cancer Institute - H072, Hershey, PA
⁸University of California, Los Angeles, Los Angeles, CA
⁹H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

3656

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

Lewis R. Silverman, MD¹^*, Amit Verma², Rosalie Odchimar-Reissig¹^*, Amanda LeBlanc¹^*, Vesna Najfeld¹, Janice Gabrilove¹^*, Luis Isola¹^*, Igor Espinoza-Delgado, MD³^* and James Zwiebel³^*

¹Division of Hematology, Mount Sinai School of Medicine, New York, NY
²Albert Einstein College of Medicine, Bronx, NY
³Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

3657

SNP-a Karyotyping Provides a Clonal Molecular Marker and Is Associated with a High Incidence of Segmental Uniparental Disomy in Patients with CMML

Michael McDevitt, MD, PhD¹, Andrew Jeffrey Dunbar, BS²^*, Christine o'Keefe²^*, Hideki Makishima, MD, PhD³^*, Ramon V. Tiu, MD, BS⁴, Lukasz Gondek⁵^*, Judith E. Karp⁶^*, Xiao-Fei Wang⁷^*, Mark J. Levis, MD, PhD⁸ and Jaroslaw Maciejewski⁹

¹Division of Hematology, Johns Hopkins University, Baltimore, MD
²Cleveland Clinic, Cleveland, OH
³Exp. Hem. & Hematopoiesis, Taussig Cancer Center, Cleveland, OH
⁴Hematologic Oncology and Blood Disorders/Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁵Exp. Hem. & Hematopoiesis, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
⁶Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center, JHUSOM, Baltimore, MD
⁷Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
⁸Johns Hopkins University, Baltimore, MD
⁹Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH